CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 275 of 308 entries

View as:

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

Phase: N/A Priority: Normal

NCT ID: NCT00268944 Org: User:

Start: 12/31/05 End: 06/30/07 Due: 06/30/08

Immune Tolerance Induction Study

Phase: N/A Priority: Normal

NCT ID: NCT00701701 Org: User:

Start: 12/14/08 End: 02/18/20 Due: 02/18/21

A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

Phase: N/A Priority: Normal

NCT ID: NCT00074984 Org: User:

Start: 02/28/01 End: 01/31/04 Due: 01/31/05

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00003821 Org: User:

Start: 01/31/98 End: - Due: -

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

Phase: N/A Priority: Normal

NCT ID: NCT01665391 Org: User:

Start: 08/31/12 End: 11/30/14 Due: 11/30/15

Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT00308087 Org: User:

Start: 05/31/06 End: 06/30/09 Due: 06/30/10

Trilostane for Androgen-Independent Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00181597 Org: User:

Start: 03/31/04 End: 01/31/06 Due: 01/31/07

Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

Phase: N/A Priority: Normal

NCT ID: NCT00344825 Org: User:

Start: 01/31/04 End: 11/30/06 Due: 11/30/07

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Phase: N/A Priority: Normal

NCT ID: NCT02843035 Org: User:

Start: 01/04/17 End: 10/30/26 Due: 10/30/27

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT01710826 Org: User:

Start: 10/31/12 End: 02/28/13 Due: 02/28/14

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

Phase: N/A Priority: Normal

NCT ID: NCT00140621 Org: User:

Start: 07/31/05 End: 08/31/12 Due: 08/31/13

Phase I Chinese PK

Phase: N/A Priority: Normal

NCT ID: NCT00503711 Org: User:

Start: 09/30/06 End: 11/30/07 Due: 11/30/08

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00923182 Org: User:

Start: 02/28/10 End: 08/31/11 Due: 08/31/12

Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee

Phase: N/A Priority: Normal

NCT ID: NCT03190369 Org: User:

Start: 08/21/17 End: 01/28/19 Due: 01/28/20

Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal

NCT ID: NCT00125385 Org: User:

Start: 07/31/05 End: 09/30/08 Due: 09/30/09

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Phase: N/A Priority: Normal

NCT ID: NCT00017550 Org: User:

Start: 09/30/00 End: 11/30/03 Due: 11/30/04

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Phase: N/A Priority: Normal

NCT ID: NCT00853242 Org: User:

Start: 02/28/09 End: 08/31/09 Due: 08/31/10

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

Phase: N/A Priority: Normal

NCT ID: NCT06421714 Org: User:

Start: 08/16/18 End: 10/14/18 Due: 10/14/19

Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter

Phase: N/A Priority: Normal

NCT ID: NCT00454220 Org: User:

Start: 07/31/07 End: 07/31/11 Due: 07/31/12

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Phase: N/A Priority: Normal

NCT ID: NCT02255656 Org: User:

Start: 01/07/15 End: 07/15/20 Due: 07/15/21

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

Phase: N/A Priority: Normal

NCT ID: NCT02536911 Org: User:

Start: 09/30/15 End: 12/31/16 Due: 12/31/17

A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease

Phase: N/A Priority: Normal

NCT ID: NCT00229736 Org: User:

Start: 11/30/04 End: 03/31/13 Due: 03/31/14

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Phase: N/A Priority: Normal

NCT ID: NCT00158600 Org: User:

Start: 09/30/05 End: 09/30/07 Due: 09/30/08

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Phase: N/A Priority: Normal

NCT ID: NCT00358943 Org: User:

Start: 04/01/91 End: 01/31/34 Due: 01/31/35

A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable

Phase: N/A Priority: Normal

NCT ID: NCT00924443 Org: User:

Start: 06/30/04 End: 03/31/08 Due: 03/31/09

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support	NCT00268944	Genzyme, a Sanofi Company	user2@example.com	None	2005-12-31	2007-06-30	2008-06-30	-	-	2025-07-14
Immune Tolerance Induction Study	NCT00701701	Genzyme, a Sanofi Company	user2@example.com	None	2008-12-14	2020-02-18	2021-02-18	-	-	2025-07-14
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease	NCT00074984	Genzyme, a Sanofi Company	user2@example.com	None	2001-02-28	2004-01-31	2005-01-31	-	-	2025-07-14
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer	NCT00003821	Genzyme, a Sanofi Company	user2@example.com	None	1998-01-31	-	-	-	-	2025-07-14
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)	NCT01665391	Genzyme, a Sanofi Company	user2@example.com	None	2012-08-31	2014-11-30	2015-11-30	-	-	2025-07-14
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma	NCT00308087	Genzyme, a Sanofi Company	user2@example.com	None	2006-05-31	2009-06-30	2010-06-30	-	-	2025-07-14
Trilostane for Androgen-Independent Prostate Cancer	NCT00181597	Genzyme, a Sanofi Company	user2@example.com	None	2004-03-31	2006-01-31	2007-01-31	-	-	2025-07-14
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)	NCT00344825	Genzyme, a Sanofi Company	user2@example.com	None	2004-01-31	2006-11-30	2007-11-30	-	-	2025-07-14
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	NCT02843035	Genzyme, a Sanofi Company	user2@example.com	None	2017-01-04	2026-10-30	2027-10-30	-	-	2025-07-14
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers	NCT01710826	Genzyme, a Sanofi Company	user2@example.com	None	2012-10-31	2013-02-28	2014-02-28	-	-	2025-07-14
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	NCT00140621	Genzyme, a Sanofi Company	user2@example.com	None	2005-07-31	2012-08-31	2013-08-31	-	-	2025-07-14
Phase I Chinese PK	NCT00503711	Genzyme, a Sanofi Company	user2@example.com	None	2006-09-30	2007-11-30	2008-11-30	-	-	2025-07-14
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	NCT00923182	Genzyme, a Sanofi Company	user2@example.com	None	2010-02-28	2011-08-31	2012-08-31	-	-	2025-07-14
Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee	NCT03190369	Genzyme, a Sanofi Company	user2@example.com	None	2017-08-21	2019-01-28	2020-01-28	-	-	2025-07-14
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	NCT00125385	Genzyme, a Sanofi Company	user2@example.com	None	2005-07-31	2008-09-30	2009-09-30	-	-	2025-07-14
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome	NCT00017550	Genzyme, a Sanofi Company	user2@example.com	None	2000-09-30	2003-11-30	2004-11-30	-	-	2025-07-14
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis	NCT00853242	Genzyme, a Sanofi Company	user2@example.com	None	2009-02-28	2009-08-31	2010-08-31	-	-	2025-07-14
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants	NCT06421714	Genzyme, a Sanofi Company	user2@example.com	None	2018-08-16	2018-10-14	2019-10-14	-	-	2025-07-14
Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter	NCT00454220	Genzyme, a Sanofi Company	user2@example.com	None	2007-07-31	2011-07-31	2012-07-31	-	-	2025-07-14
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409	NCT02255656	Genzyme, a Sanofi Company	user2@example.com	None	2015-01-07	2020-07-15	2021-07-15	-	-	2025-07-14
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	NCT02536911	Genzyme, a Sanofi Company	user2@example.com	None	2015-09-30	2016-12-31	2017-12-31	-	-	2025-07-14
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease	NCT00229736	Genzyme, a Sanofi Company	user2@example.com	None	2004-11-30	2013-03-31	2014-03-31	-	-	2025-07-14
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease	NCT00158600	Genzyme, a Sanofi Company	user2@example.com	None	2005-09-30	2007-09-30	2008-09-30	-	-	2025-07-14
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry	NCT00358943	Genzyme, a Sanofi Company	user2@example.com	None	1991-04-01	2034-01-31	2035-01-31	-	-	2025-07-14
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable	NCT00924443	Genzyme, a Sanofi Company	user2@example.com	None	2004-06-30	2008-03-31	2009-03-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance